Clinical trials: Stage IV NSCLC
NSCLC Stage IV, PD-L1 Gene Mutation
TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50%
This prospective, multicenter, real-world observational study aims to evaluate the clinical outcomes of first-line atezolizumab monotherapy in patients with stage IV non-small cell lung cancer (NSCLC) with PD-L1 tumor cell…
- Conditions
- NSCLC Stage IV, PD-L1 Gene Mutation, Atezolizumab, Real World Study
- Trial name
- NCT07279402
- Where
- 25 sites in Turkey (Türkiye)
- Volunteers
- 150 people
- Sponsor
- Antalya Training and Research Hospital
NSCLC Stage IV, EGFR Gene Mutation
A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy
Efficacy and Safety of Sacituzumab Tirumotecan Combined with Furmonertinib in Patients with Locally Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy.
- Trial name
- TROP-LUNG (NCT07548060)
- Testing
- sacituzumab tirumotecan
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
NSCLC Stage IIIB~IV
A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.
using Atezolizumab, a PD-L1 inhibitor, in combination with bevacizumab, platinum and pemetrexed to treat patients with EGFR mutated, advanced non-small cell lung cancer (NSCLC) after failure of EGFR tyrosine kinase inhibitors.
- Trial name
- NCT04147351
- Testing
- Atezolizumab Injection; bevacizumab Injection
- Where
- Taiwan
- Volunteers
- 22 people
- Sponsor
- National Taiwan University Hospital
Non-small Cell Lung Cancer (NSCLC), Stage IV
Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer Patients
Unfortunately, most patients are already at a very advanced stage when they are diagnosed with lung cancer, i.e. the cancer has already spread outside the lungs forming metastases.
- Trial name
- salVage (NCT06114108)
- Testing
- Systemic therapy alone or in combination with LAT (surgery and/or radiotherapy), Surgery, Radiotherapy
- Where
- 7 sites in Switzerland
- Volunteers
- 128 people
- Sponsor
- Swiss Cancer Institute
NSCLC Stage IV
18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC
A multicenter single arm biomarker exploration and validation study. Eighty patients with NSCLC that are eligible for first line chemo-immunotherapy, first line nivolumab/ipilimumab or 2nd line and beyond PD-(L)1 immunotherapy…
- Trial name
- NCT03564197
- Testing
- 18F-PD-L1
- Where
- 8 sites in Netherlands
- Volunteers
- 80 people
- Sponsor
- The Netherlands Cancer Institute
TNBC - Triple-Negative Breast Cancer, Triple Negative Breast Cancer
Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung
The purpose of this study is determine if receiving stereotactic body radiation(SBRT) when participants' metastatic tumors have just begun to grow increase the length of time before disease gets worse
- Conditions
- TNBC - Triple-Negative Breast Cancer, Triple Negative Breast Cancer, NSCLC, NSCLC Stage IV
- Trial name
- NCT03808662
- Testing
- Sterotactic Body Radiotherapy/SBRT, Standard of care
- Where
- 10 sites in United States, Canada
- Volunteers
- 107 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lung Cancer, NSCLC
Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients
This is an open-label, non-randomised, phase II, exploratory, multi-country and multi-centre clinical trial. Chemotherapy-naïve patients with EML4-ALK rearrangement and with locally advanced or metastatic non-small cell lung…
- Conditions
- Lung Cancer, NSCLC, NSCLC Stage IIIB, NSCLC Stage IV
- Trial name
- CUBIK (NCT04223596)
- Testing
- Brigatinib
- Where
- 15 sites in Spain
- Volunteers
- 33 people
- Sponsor
- Fundación GECP
Non-small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to see whether receiving local ablative therapy (LAT) when minimal residual disease/MRD levels are rising can reduce MRD levels and control metastatic non-small cell lung cancer/NSCLC longer compared…
- Conditions
- Non-small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Nsclc, NSCLC Stage IV
- Trial name
- NCT05429320
- Testing
- Local ablative therapy, Blood collection to assess for ctDNA
- Where
- 9 sites in United States
- Volunteers
- 37 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
NSCLC Stage IV, NSCLC, Recurrent
Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC
The purpose of this study is to see if adding pirfenidone to atezolizumab will increase anti tumor activity and reduce treatment resistance in stage 4 and recurrent non- small cell lung cancer participants.
- Trial name
- NCT04467723
- Testing
- Atezolizumab
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of Kansas Medical Center
NSCLC Stage IV, EGFR Positive Non-small Cell Lung Cancer
Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mg
This study evaluates the efficacy and safety of Firmonertinib 160 mg once daily in patients with EGFR-mutant, advanced NSCLC who achieve stable disease after first-line Firmonertinib 80 mg for 8 weeks.
- Conditions
- NSCLC Stage IV, EGFR Positive Non-small Cell Lung Cancer, EGFR-TKI Sensitizing Mutation
- Trial name
- NCT07298148
- Testing
- Firmonertinib 160mg
- Volunteers
- 28 people
- Sponsor
- Peking University Cancer Hospital & Institute
NSCLC Stage IV, KRAS G12C
Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC
This study evaluates the safety, tolerability, maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and recommended phase II dose (RP2D) of Glecirasib in combination with Ivonescimab in patients with previously…
- Trial name
- NCT07339839
- Testing
- Glecirasib, Ivonescimab
- Volunteers
- 42 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NSCLC, NSCLC Stage IV
Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer
This is a Phase I open label multi-center study to evaluate the safety, tolerability, pharmacokinetics and preliminary effectiveness of the investigational drug MYTX-011 in patients with locally advanced, recurrent or metastatic…
- Conditions
- NSCLC, NSCLC Stage IV, NSCLC Stage IIIB, Non-Small Cell Lung Cancer
- Trial name
- NCT05652868
- Testing
- MYTX-011
- Where
- 55 sites in United States, Australia and 5 more
- Volunteers
- 227 people
- Sponsor
- Mythic Therapeutics
NSCLC Stage IV
Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC
Multicentre, phase II, open-label, single-arm study evaluating the preliminary efficacy, safety and tolerability of atezolizumab in association with palliative radiotherapy in adult patients diagnosed with advanced (stage IV)…
- Trial name
- NCT04549428
- Testing
- Atezolizumab
- Where
- 3 sites in Switzerland
- Volunteers
- 12 people
- Sponsor
- Oncology Institute of Southern Switzerland
Stage IV NSCLC, NSCLC
Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Cancer
The purpose of this study is to learn the effects of fasting on cancer cells while you get maintenance treatment.
- Conditions
- Stage IV NSCLC, NSCLC, Immunotherapy, Fasting Mimicking Diet
- Trial name
- Stage IV NSCLC (NCT06671613)
- Testing
- FMD, Regular Diet Plus FMD
- Where
- 4 sites in United States
- Volunteers
- 66 people
- Sponsor
- VA Office of Research and Development
Lung Cancer Metastatic, NSCLC Stage IV
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
This is an open-label, multi-center, single arm, phase II study to assess the anti-tumor activity and safety of bemcentinib in combination with pembrolizumab in up to 106 participants with previously treated, advanced…
- Conditions
- Lung Cancer Metastatic, NSCLC Stage IV, Adenocarcinoma of Lung
- Trial name
- NCT03184571
- Testing
- Pembrolizumab, Bemcentinib
- Where
- 13 sites in United States, Norway and 2 more
- Volunteers
- 99 people
- Sponsor
- BerGenBio ASA
Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage IIIB
Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer
This study aimed to evaluate the safety and effectiveness of ociperlimab combined with tislelizumab and chemotherapy, compared to tislelizumab and chemotherapy alone, in participants with non-small cell lung cancer (NSCLC) that…
- Conditions
- Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC), Nonsmall Cell Lung Cancer, Stage IIIB, Nonsmall Cell Lung Cancer, Stage IV
- Trial name
- NCT05014815
- Testing
- Ociperlimab, Tislelizumab, Carboplatin
- Where
- 64 sites in United States, Australia and 6 more
- Volunteers
- 272 people
- Sponsor
- BeiGene
NSCLC, Stage III, NSCLC, Stage IV
A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer
Androgen Deprivation Therapy (ADT) triggers thymic revitalization and increases thymic output, enhancing baseline anti-tumor immunity and responses to immunotherapies.
- Trial name
- NCT06512207
- Testing
- Leuprorelin acetate + Sintilimab, Sintilimab
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Jinzhou Medical University
NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC Stage IIIB~IV
Immune-Marker Platform for Patients With Advanced Lung Cancer
The goal of this observational study is to better understand how the immune system and certain tumor markers are linked to treatment response in patients with advanced non-small cell lung cancer (NSCLC) who receive…
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC Stage IIIB~IV, NSCLC Non-small Cell Lung Cancer
- Trial name
- IMPALUX (NCT07150598)
- Where
- 2 sites in Germany
- Volunteers
- 500 people
- Sponsor
- Technische Universität Dresden
NSCLC Stage IV
A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients
A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab (Anti-PD-1 Humanized Monoclonal Antibody Injection) and Chemotherapy in Previously…
- Trial name
- NCT05787613
- Testing
- HLX26, Serplulimab, Chemotherapy drug
- Where
- 3 sites in China
- Volunteers
- 132 people
- Sponsor
- Shanghai Henlius Biotech
NSCLC Stage IV, Melanoma Stage IV
Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and Melanoma
Modulating the gut microbiome to improve response to immune-checkpoint inhibitors is an active area of study. Prebiotic substances (compounds which positively shift the gut microbiome) are a reliable and safe method of gut…
- Conditions
- NSCLC Stage IV, Melanoma Stage IV, Unresectable Melanoma, Advanced Non-Small Cell Lung Cancer
- Trial name
- NCT05303493
- Testing
- Camu Camu Capsules (Camu Camu powder encapsulated (500mg each) + ICI
- Where
- 3 sites in Canada
- Volunteers
- 45 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)